All the news Showing 10 of 448 articles from: TherapiesGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Achillion Announces 100% SVR Reported in Janssen’s Phase 2a Trial Evaluating Triple Combination of Odalasvir, AL-335, and Simeprevir for Genotype 1 Treatment-Naive HCV Achillion press release / 09 September 2016 European Commission Grants Marketing Authorisation for MSD’s ZEPATIER™ (elbasvir/grazoprevir) for the Treatment of Chronic Hepatitis C Infection MSD press release / 02 August 2016 CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A) Manual Items / 26 July 2016 European Commission Grants Marketing Authorization for Gilead’s Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C Gilead press release / 08 July 2016 FDA places RG-101 for HCV on clinical hold Healio / 05 July 2016 FDA Approves Gilead's Epclusa Combo Pill for All Hepatitis C Genotypes HIVandHepatitis.com / 04 July 2016 Washington Ordered to Cover Hepatitis C Drugs During Lawsuit Bloomberg / 31 May 2016 Merck Receives Positive CHMP Opinion for ZEPATIER™ (elbasvir and grazoprevir) in the European Union MSD press release / 30 May 2016 AbbVie receives CHMP positive opinion for VIEKIRAX® + EXVIERA® without ribavirin for the treatment of HCV in GT1b patients with compensated cirrhosis in Europe AbbVie press release / 02 March 2016 RG-101 Interim Analysis Shows 97% Response at 8 Week Follow-Up Regulus Therapeutics press release / 17 February 2016 ← Prev1...23456...45Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Transmission and prevention Diagnosis and monitoring Disease course and symptoms HCV and coinfections Living with HCV Treatment issues Side effects Therapies Liver transplants Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive